CN115484985A - 温度响应病毒储存系统 - Google Patents
温度响应病毒储存系统 Download PDFInfo
- Publication number
- CN115484985A CN115484985A CN202180021868.8A CN202180021868A CN115484985A CN 115484985 A CN115484985 A CN 115484985A CN 202180021868 A CN202180021868 A CN 202180021868A CN 115484985 A CN115484985 A CN 115484985A
- Authority
- CN
- China
- Prior art keywords
- composition
- tromethamine
- amount
- cyclodextrin
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10061—Methods of inactivation or attenuation
- C12N2710/10063—Methods of inactivation or attenuation by chemical treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062991671P | 2020-03-19 | 2020-03-19 | |
US62/991,671 | 2020-03-19 | ||
PCT/IB2021/000157 WO2021186246A1 (en) | 2020-03-19 | 2021-03-19 | Temperature-responsive virus storage system |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115484985A true CN115484985A (zh) | 2022-12-16 |
Family
ID=75919336
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202180021868.8A Pending CN115484985A (zh) | 2020-03-19 | 2021-03-19 | 温度响应病毒储存系统 |
Country Status (11)
Country | Link |
---|---|
US (3) | US20230175012A1 (de) |
EP (1) | EP4121115A1 (de) |
JP (1) | JP2023519120A (de) |
KR (1) | KR20230013021A (de) |
CN (1) | CN115484985A (de) |
AU (1) | AU2021237818A1 (de) |
BR (1) | BR112022018615A2 (de) |
CA (1) | CA3168761A1 (de) |
IL (1) | IL296520A (de) |
TW (1) | TW202200197A (de) |
WO (1) | WO2021186246A1 (de) |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6835557B1 (en) | 1980-01-08 | 2004-12-28 | Biogen, Inc. | DNA sequences, recombinant DNA molecules and processes for producing human interferon-like polypeptides |
US4414150A (en) | 1980-11-10 | 1983-11-08 | Genentech, Inc. | Hybrid human leukocyte interferons |
AU561343B2 (en) | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
US4855238A (en) | 1983-12-16 | 1989-08-08 | Genentech, Inc. | Recombinant gamma interferons having enhanced stability and methods therefor |
DE3410439A1 (de) | 1984-03-22 | 1985-09-26 | Hoechst Ag, 6230 Frankfurt | Verfahren zur herstellung von 6-methyl-3,4-dihydro-1,2,3-oxathiazin-4-on-2,2-dioxid und dessen nichttoxischen salzen sowie der dabei als zwischenprodukt(e) auftretenden acetoacetamind-n-sulfonsaeure(salze) |
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US6210939B1 (en) | 1993-10-25 | 2001-04-03 | Canji, Inc. | Recombinant adenoviral vector and methods of use |
US6392069B2 (en) | 1996-01-08 | 2002-05-21 | Canji, Inc. | Compositions for enhancing delivery of nucleic acids to cells |
FR2751343B1 (fr) | 1996-07-16 | 1998-12-18 | Transgene Sa | Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament |
US6544769B1 (en) * | 1996-12-13 | 2003-04-08 | Schering Corporation | Compostions comprising viruses and methods for concentrating virus preparations |
US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
WO2001029058A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
CN101396555A (zh) * | 2003-06-04 | 2009-04-01 | 坎基股份有限公司 | 用于干扰素治疗的方法和组合物 |
CN1893981B (zh) | 2003-12-10 | 2011-03-23 | 坎基股份有限公司 | 用于治疗干扰素耐药性肿瘤的方法和组合物 |
MX2018002586A (es) * | 2015-09-01 | 2020-11-24 | First Wave Bio Inc | Composiciones para usarse en el tratamiento de afecciones asociadas a una repsuesta inflamatoria anómala. |
US11104915B2 (en) | 2015-09-15 | 2021-08-31 | Trizell Ltd. | Viral vector assay and vector |
EP3442588A4 (de) | 2016-04-14 | 2020-02-19 | Trizell Ltd. | Stabilisierung von virusvektoren |
KR20220141280A (ko) * | 2019-12-11 | 2022-10-19 | 엔이1 인코퍼레이티드 | 암 면역요법을 위한 개인맞춤형 종양 백신 및 이의 용도 |
-
2021
- 2021-03-19 US US17/912,103 patent/US20230175012A1/en active Pending
- 2021-03-19 CN CN202180021868.8A patent/CN115484985A/zh active Pending
- 2021-03-19 WO PCT/IB2021/000157 patent/WO2021186246A1/en unknown
- 2021-03-19 IL IL296520A patent/IL296520A/en unknown
- 2021-03-19 KR KR1020227036164A patent/KR20230013021A/ko active Search and Examination
- 2021-03-19 CA CA3168761A patent/CA3168761A1/en active Pending
- 2021-03-19 JP JP2022550922A patent/JP2023519120A/ja active Pending
- 2021-03-19 BR BR112022018615A patent/BR112022018615A2/pt unknown
- 2021-03-19 EP EP21725806.0A patent/EP4121115A1/de active Pending
- 2021-03-19 AU AU2021237818A patent/AU2021237818A1/en active Pending
- 2021-03-19 TW TW110110090A patent/TW202200197A/zh unknown
-
2023
- 2023-10-19 US US18/381,782 patent/US20240043873A1/en active Pending
- 2023-12-13 US US18/538,052 patent/US20240117379A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2021186246A1 (en) | 2021-09-23 |
AU2021237818A1 (en) | 2022-09-29 |
US20230175012A1 (en) | 2023-06-08 |
CA3168761A1 (en) | 2021-09-23 |
TW202200197A (zh) | 2022-01-01 |
EP4121115A1 (de) | 2023-01-25 |
US20240117379A1 (en) | 2024-04-11 |
IL296520A (en) | 2022-11-01 |
KR20230013021A (ko) | 2023-01-26 |
US20240043873A1 (en) | 2024-02-08 |
BR112022018615A2 (pt) | 2022-12-20 |
JP2023519120A (ja) | 2023-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6800863B2 (ja) | 最適化されたヒト凝固第viii因子遺伝子発現カセットおよびその使用 | |
ES2290613T3 (es) | Composiciones que comprenden virus y metodos para concentrar preparaciones de virus. | |
CN106471125B (zh) | 包括白蛋白结合部分的腺病毒 | |
Hofherr et al. | Polyethylene glycol modification of adenovirus reduces platelet activation, endothelial cell activation, and thrombocytopenia | |
US10744172B2 (en) | Tropism modified cancer terminator virus (Ad.5/3 CTV;Ad.5/3-CTV-M7) | |
JP2010539923A (ja) | 組織特異的プロモーターと腫瘍を標的とするトランススプライシングリボザイムとを含む組換えアデノウイルス及びその用途 | |
KR20010074441A (ko) | 폴리뉴클레오티드 조성물, 이의 제조방법, 및 용도 | |
CN110996980B (zh) | 一种用于治疗肿瘤的病毒 | |
KR20060012661A (ko) | 인터페론 요법을 위한 방법 및 조성물 | |
JP2010095549A (ja) | Syn3組成物およびその方法 | |
JP5547640B2 (ja) | 前立腺癌の治療・予防剤 | |
Gou et al. | Non‐Pore Dependent and MMP‐9 Responsive Gelatin/Silk Fibroin Composite Microparticles as Universal Delivery Platform for Inhaled Treatment of Lung Cancer | |
CN109568350B (zh) | 一种用于治疗肿瘤的柯萨奇病毒 | |
CN100429220C (zh) | 用于干扰素治疗的方法和组合物 | |
CN115484985A (zh) | 温度响应病毒储存系统 | |
WO2019201192A1 (zh) | 一种用于治疗肿瘤的柯萨奇b组病毒 | |
US20200010850A1 (en) | Efficient cell free production of papillomavirus gene transfer vectors | |
JP2020537534A (ja) | 腫瘍を治療するためのエコーウイルス | |
Fujita et al. | Sendai virus-mediated gene delivery into hepatocytes via isolated hepatic perfusion | |
KR20190082134A (ko) | 유전자 전달용 세포 시트 | |
US20230348935A1 (en) | Vaccine compositions for mucosal immune response | |
Henderson et al. | Development of attenuated replication competent adenoviruses (ARCAs) for the treatment of prostate cancer | |
EP2875831A1 (de) | Verfahren zur genetischen Übertragung in eine eukaryotische Zelle durch einen viralen Vektor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |